Tiziana Life Sciences plc to expedite development of TZLS-501 for COVID-19 Medical Dialogues Bureau13 March 2020 5:45 AM GMTTiziana's anti-IL-6R mAb binds to both the membrane-bound and soluble forms of IL-6R and rapidly depletes circulating levels of IL-6 in the blood.